Mirati Therapeutics Inc MRTX

NAS: MRTX | ISIN: US60468T1051   22/01/2024
58,70 USD (-0,17%)
(-0,17%)   22/01/2024
Grafiek Mirati Therapeutics Inc Grafiek Mirati Therapeutics Inc

Mirati Therapeutics Inc in het nieuws

10 januari 2024 · European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation · Persbericht

10 november 2023 · Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure · Persbericht

6 november 2023 · Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates · Persbericht

3 november 2023 · Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation · Persbericht

31 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, PCTI, MRTX · Persbericht

26 oktober 2023 · Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm · Persbericht

17 oktober 2023 · Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC) · Persbericht

17 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNSL, PCTI, SP, MRTX · Persbericht

10 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWLI, MRTX, SLGC, PNT · Persbericht

9 oktober 2023 · Shareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers Squibb · Persbericht

Profiel Mirati Therapeutics Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.mirati.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Charles Baum

Werknemers: 593

Aandelen Mirati Therapeutics Inc

Effecten: 70,15 miljoen

Winst per aandeel (12 maand):  PLUS

Mijn selecties